Source Data Figure 1 .xlsx

e, Cell viability of human osteoarthritis (OA) chondrocytes assessed using
the alamar blue assay at 1 d, 3 d, 5 d, and 7 d after BNTA treatment (n = 14
for each group; 1 d, nonparametric test; 3 d, 5 d, and 7 d, one-way ANOVA). f, Quantification of mRNA levels for collagen
type II alpha 1 chain (COL2A1), aggrecan (ACAN), proteoglycan 4 (PRG4), and SRY-box 9 (SOX9) in human OA chondrocytes treated
with BNTA for 6 h. Fold changes relative to vehicle control are shown (n = 6
for each group; COL2A1, ACAN, SOX9, one-way ANOVA; PRG4,
nonparametric test; three independent experiments). g, The mRNA levels of Col2a1, Acan, Prg4, and Sox9 in interleukin 1 beta ( IL1β, 10 ng
ml-1)-induced rat OA chondrocytes treated with BNTA for 6 h (n = 6
for each group; Col2a1, one-way ANOVA;
Acan, Prg4, and Sox9,
nonparametric test; three independent experiments). h, The proteins levels of SOX9 and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) in human OA chondrocytes treated with vehicle or BNTA
(0.1 μM) for 2d. i, The proteins
levels of COL2A1, SOX9, and GAPDH were detected using western blotting assay in
IL1β (10 ng ml-1)-induced rat OA chondrocytes treated with or
without BNTA (0.1 μM) for 2d. All data are shown as the mean ± standard
deviation (s. d.). *P < 0.05, **P < 0.01, ***P < 0.001.